|
|
|
Dynavax Technologies Corp (DVAX)
Dynavax Technologies is a commercial stage biopharmaceutical company engaged in developing and commercializing vaccines. Co.'s primary marketed product, Hepatitis B Vaccine (Recombinant), Adjuvanted (HEPLISAV-B), is approved in the U.S. and European Union for prevention of infection caused by known subtypes of hepatitis B virus in adults age 18 years and older. Co. also manufactures and sells CpG oligonucleotide (CpG) 1018 adjuvant, the vaccine adjuvant used in HEPLISAV-B. Co. developed CpG 1018 adjuvant to provide an increased vaccine immune response.
Name: |
Dynavax Technologies Corp |
Website: |
www.dynavax.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding DVAX: |
50 (see which ones) |
Total Market Value Held by ETFs: |
$355,908,719.52 |
Total Market Capitalization: |
$1,492,000,000 |
% of Market Cap. Held by ETFs: |
23.85% |
|
|
|
Strong Buy (3.60 out of 4)
66th percentile
|
|
|